KYODO NEWS IMAGELINK

報道写真の購入なら共同通信イメージズ

「ロシア直接投資基金」の写真・グラフィックス・映像

絞り込み
  • 提供元
  • 日付
  • 種類
  • 向き
  • カテゴリ
並び順
  • 古い順
5
( 1 5 件を表示)
  • 1
5
( 1 5 件を表示)
絞り込み
並び順
  • 古い順
  • 2021年04月19日
    Russian Sputnik V COVID-19 Vaccine

    April 19, 2021, Asuncion, Paraguay: Illustration photo - Logo of Russia‘s Sputnik V vaccine is displayed on a smartphone in front of visual representation of virus, medical syringe and ampoules with label COVID-19 vaccine. The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF) today announced that the Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia. (Credit Image: © Andre M. Chang/ZUMA Wire)、クレジット:©Andre M. Chang/ZUMA Wire/共同通信イメージズ

    商品コード: 2021042009484

  • 2021年04月19日
    Russian Sputnik V COVID-19 Vaccine

    April 19, 2021, Asuncion, Paraguay: Illustration photo - Logo of Russia‘s Sputnik V vaccine is displayed on a smartphone in front of visual representation of virus, medical syringe and ampoules with label COVID-19 vaccine. The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF) today announced that the Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia. (Credit Image: © Andre M. Chang/ZUMA Wire)、クレジット:©Andre M. Chang/ZUMA Wire/共同通信イメージズ

    商品コード: 2021042009342

  • 2021年04月19日
    Russian Sputnik V COVID-19 Vaccine

    April 19, 2021, Asuncion, Paraguay: Illustration photo - Logo of Russia‘s Sputnik V vaccine is displayed on a smartphone in front of visual representation of virus, medical syringe and ampoules with label COVID-19 vaccine. The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF) today announced that the Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia. (Credit Image: © Andre M. Chang/ZUMA Wire)、クレジット:©Andre M. Chang/ZUMA Wire/共同通信イメージズ

    商品コード: 2021042009523

  • 2021年04月19日
    Russian Sputnik V COVID-19 Vaccine

    April 19, 2021, Asuncion, Paraguay: Illustration photo - Logo of Russia‘s Sputnik V vaccine is displayed on a smartphone in front of visual representation of virus, medical syringe and ampoules with label COVID-19 vaccine. The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF) today announced that the Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia. (Credit Image: © Andre M. Chang/ZUMA Wire)、クレジット:©Andre M. Chang/ZUMA Wire/共同通信イメージズ

    商品コード: 2021042005279

  • 2021年04月19日
    Russian Sputnik V COVID-19 Vaccine

    April 19, 2021, Asuncion, Paraguay: Illustration photo - Logo of Russia‘s Sputnik V vaccine is displayed on a smartphone in front of visual representation of virus, medical syringe and ampoules with label COVID-19 vaccine. The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF) today announced that the Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia. (Credit Image: © Andre M. Chang/ZUMA Wire)、クレジット:©Andre M. Chang/ZUMA Wire/共同通信イメージズ

    商品コード: 2021042009524

  • 1